Alithya Correlations
| ALYAF Stock | 1.21 0.04 3.42% |
The current 90-days correlation between Alithya Group and Appen Limited is -0.05 (i.e., Good diversification). The correlation of Alithya is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Alithya Correlation With Market
Significant diversification
The correlation between Alithya Group and DJI is 0.04 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Alithya Group and DJI in the same portfolio, assuming nothing else is changed.
Moving together with Alithya Stock
| 0.75 | FISV | Fiserv Common Stock Symbol Change | PairCorr |
Moving against Alithya Stock
| 0.57 | CTSH | Cognizant Technology Sell-off Trend | PairCorr |
| 0.43 | NECPY | NEC ADR | PairCorr |
| 0.41 | IBM | International Business | PairCorr |
| 0.4 | CGEMY | Capgemini SE ADR | PairCorr |
| 0.39 | NCRRP | NCR Corp Pref | PairCorr |
| 0.39 | INFY | Infosys Ltd ADR Aggressive Push | PairCorr |
| 0.37 | ACN | Accenture plc | PairCorr |
| 0.37 | CAPMF | Capgemini SE | PairCorr |
| 0.37 | ERHE | ERHC Energy | PairCorr |
| 0.65 | XMTR | Xometry | PairCorr |
| 0.64 | GOOG | Alphabet Class C | PairCorr |
| 0.5 | TMO | Thermo Fisher Scientific | PairCorr |
| 0.46 | ASCLF | Ascletis Pharma | PairCorr |
| 0.45 | NLY-PF | Annaly Capital Management | PairCorr |
| 0.43 | SUTNY | Sumitomo Mitsui Trust | PairCorr |
| 0.39 | NLY-PJ | Annaly Capital Management | PairCorr |
| 0.33 | WU | Western Union | PairCorr |
| 0.6 | HASI | Hannon Armstrong Sus | PairCorr |
| 0.59 | CINF | Cincinnati Financial | PairCorr |
| 0.59 | TEVA | Teva Pharma Industries | PairCorr |
| 0.54 | GM | General Motors Sell-off Trend | PairCorr |
| 0.53 | KXIAY | Kioxia Holdings | PairCorr |
| 0.48 | AVBC | Avidia Bancorp | PairCorr |
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Alithya Stock performing well and Alithya Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Alithya's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| APPEF | 1.03 | 0.24 | 0.00 | 4.51 | 0.00 | 5.88 | 18.96 | |||
| CNGFF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| DCHIY | 0.42 | (0.20) | 0.00 | 2.46 | 0.00 | 0.00 | 9.76 | |||
| FCCN | 3.20 | 1.22 | 0.36 | (3.28) | 2.22 | 4.52 | 51.06 | |||
| QSCGF | 1.40 | 0.33 | 0.00 | (1.16) | 0.00 | 0.00 | 38.78 | |||
| SDIIF | 0.27 | (0.07) | 0.00 | 0.63 | 0.00 | 0.00 | 9.09 | |||
| WONDF | 2.14 | 0.02 | 0.00 | 0.05 | 0.00 | 5.56 | 10.82 | |||
| ADPXY | 1.97 | 1.08 | 0.00 | (0.22) | 0.00 | 1.50 | 58.48 | |||
| FHGDF | 2.47 | 0.24 | 0.00 | 0.21 | 0.00 | 12.50 | 61.90 | |||
| TDMMF | 1.67 | 0.01 | 0.00 | 0.09 | 0.00 | 0.00 | 55.17 |
Alithya Corporate Management
| David Torralbo | Chief Secretary | Profile | |
| Nigel Fonseca | Senior Canada | Profile | |
| Giulia Cirillo | Chief Officer | Profile | |
| John Scandar | Senior Practice | Profile | |
| Bernard Dockrill | Chief Officer | Profile |